RE: Simultaneous drug and metabolite POPPK
I just performed this kind of population analysis (with pdx-MC-PEM , not
NONMEM) and there was no problem. In fact I never changed the units that
were in ng/ml for both the drug parent and 7 metabolites. I think (I can
be wrong of course) that the model parameters take care of everything
automatically. The model parameters will have the units that include the
conversion needed (from ng to nanmoles).
Serge Guzy
President, CEO; POP-PHARM, Inc.
_____
Quoted reply history
From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED]
On Behalf Of Xiao, Alan
Sent: Tuesday, February 13, 2007 6:49 AM
To: [EMAIL PROTECTED]; Nmusers (E-mail);
[EMAIL PROTECTED]
Subject: RE: [NMusers] Simultaneous drug and metabolite POPPK
I think the easiest and least confusing way is to transform all
concentrations into molar units in your data sets at the beginning when
you model parent and metabolites simultaneously. However, there are
other options to go around this issue. For example, you can also
incorporate molecular weights into your model if you have to use weight
concentrations in your data set for some reason.
Alan
-----Original Message-----
From: [EMAIL PROTECTED]
[mailto:[EMAIL PROTECTED] Behalf Of
[EMAIL PROTECTED]
Sent: Tuesday, February 13, 2007 9:02 AM
To: Nmusers (E-mail); [EMAIL PROTECTED]
Subject: RE: [NMusers] Simultaneous drug and metabolite POPPK
I have a question for those who submitted these two examples -
Did you transform the data into micromolar quantities? It is not clear
from the examples. I have not done much parent/metabolite modeling (just
lucky I guess) but it seems to me that one would have to work in molar
units for these models to be valid. Can someone comment on this?
Mike
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Michael J. Fossler, Pharm. D., Ph. D., F.C.P.
Director
Clinical Pharmacokinetics, Modeling & Simulation
GlaxoSmithKline
(610) 270 - 4797
FAX: (610) 270-5962
Cell: (443) 350-1194
[EMAIL PROTECTED]
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
--
The information contained in this email message may contain confidential or
legally privileged information and is intended solely for the use of the named
recipient(s). No confidentiality or privilege is waived or lost by any
transmission error. If the reader of this message is not the intended
recipient, please immediately delete the e-mail and all copies of it from your
system, destroy any hard copies of it and notify the sender either by telephone
or return e-mail. Any direct or indirect use, disclosure, distribution,
printing, or copying of any part of this message is prohibited. Any views
expressed in this message are those of the individual sender, except where the
message states otherwise and the sender is authorized to state them to be the
views of XOMA.